SPDR S&P Biotech (XBI)

Add to Watchlists Create an Alert
160.38 -1.57  -0.97% NYSE Arca Sep 2, 3:04PM BATS Real time Currency in USD
View Full Chart
XBI Price Chart

XBI Description

SPDR S&P Biotech is a long only equity fund managed by SPDR State Street Global Advisors that tracks the S&P Biotechnology Select Industry TR USD index and has 1.216B USD assets under management. It has an expected distribution yield of 0.20%, a Prospective PE Ratio of 32.68, and a Prospective Price to Book Value of 3.918. The fund has a net expense ratio of 0.35%, turns over its positions 86.00% per year, and is traded on the New York Stock Exchange Arca.

Benchmark Index: S&P Biotechnology Select Industry TR USD

XBI Key Info

Expense Ratio (4-4-14) 0.35%
Assets Under Management (8-29-14) 1.216B
30-Day Average Volume (8-29-14) 318250.1
Net Asset Value (8-29-14) 162.07
Discount or Premium to NAV (8-29-14) -0.07%
Turnover Ratio (6-30-14) 86.00%

XBI Asset Allocation

Type % Net % Long % Short
Cash 0.18% 0.18% 0.00%
Stock 99.82% 99.82% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Aug. 27, 2014

XBI Region Exposure

Americas 97.60%
North America 97.60%
Latin America 0.00%
Greater Europe 2.40%
United Kingdom 0.00%
Europe Developed 2.40%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of Aug. 29, 2014
Region breakdown data is calculated by using the long position holdings of the portfolio.

XBI Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of Aug. 27, 2014

XBI Stock Market Capitalization

Giant 5.81%
Large 4.16%
Medium 23.07%
Small 19.38%
Micro 47.35%
As of Aug. 27, 2014
View More Holdings

XBI Top 10 Holdings

Name % Weight Price Chg %
Puma Biotechnology Inc 5.35% 260.89 +0.15%
InterMune Inc 1.99% 73.48 +0.05%
Exact Sciences Corp 1.73% 21.03 +0.86%
Anacor Pharmaceuticals Inc 1.67% 23.39 +0.43%
Gilead Sciences Inc 1.61% 108.77 +1.12%
Pharmacyclics Inc 1.56% 123.66 -0.59%
Keryx Biopharmaceuticals Inc 1.54% 17.92 -1.48%
PTC Therapeutics Inc 1.53% 30.79 -2.75%
Receptos Inc 1.53% 52.25 +2.15%
Vertex Pharmaceuticals Inc 1.53% 92.26 -1.40%
As of Aug. 27, 2014
Get Quote for
Advertisement

XBI Risk Info

Beta 1.102
Max Drawdown (1-31-06 to 8-29-14) 37.69%
30 Day Average Volatility 31.74%

XBI Fundamentals

Distribution Yield TTM (9-2-14) 0.20%
Distribution Yield (Prospective) 0.04%
PE Ratio (Prospective) 32.68
PS Ratio (Prospective) 7.846
Price to Book Value (Prospective) 3.918
ROE -21.17%
ROA -26.22%
Number of Holdings 78.00
As of Aug. 27, 2014

XBI Growth Estimates

Forecasted 5 Yr Earnings Growth 23.17%
Forecasted Book Value Growth 9.14%
Forecasted Cash Flow Growth 27.10%
Forecasted Earnings Growth 21.49%
Forecasted Revenue Growth 1.99%
As of Aug. 27, 2014

XBI Performance

  Returns Total Returns
1M 7.72% 7.72%
3M 19.95% 20.43%
6M -2.04% -1.44%
1Y 32.83% 33.77%
3Y 156.7% 159.4%
5Y 195.3% 198.4%
As of Aug. 29, 2014

XBI Flows

1M 8.888M
3M 28.06M
6M -196.21M
YTD 39.61M
1Y -6.175M
3Y 59.90M
5Y 54.38M
As of Aug. 31, 2014
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Start My Free Trial"}}

Already a {{root.upsell.info.tier_name}} Member? Sign in here.